by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Although the ABI3 S209F variant is a recognized genetic risk for Alzheimer’s disease (AD), its pathogenic mechanism remains elusive. METHODS Using AD mouse models (amyloid precursor protein/presenilin 1 [APP/PS1] transgenic mice, 5×familial...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Epigenome-wide association studies implicate DNA methylation in Alzheimer’s disease (AD) pathology. Although recent studies identified epigenetic signatures within non-neuronal cell types in disease risk, the role of the methylome in glial...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Abstract INTRODUCTION Although Alzheimer’s disease (AD) is prevalent in individuals with chronic kidney disease (CKD), the mechanistic link remains unclear. We assessed the impact of CKD transcriptional risk on AD endophenotypes. METHODS We calculated the CKD...
by Clinical Neuropsychologist Online | Thursday, September 24, 2026 | Dementia
Dementia, Ahead of Print. The use of digital tools in reminiscence interventions has increased in recent years, encompassing multimedia platforms, virtual reality (VR), digital life storybooks, and interactive applications. Yet, evidence regarding the effectiveness of...
by Clinical Neuropsychologist Online | Wednesday, September 23, 2026 | Dementia
Abstract INTRODUCTION The apolipoprotein E (APOE) ε4 allele accelerates cognitive decline through multiple biological pathways—including neuroinflammatory, vascular, and stress-regulatory mechanisms—yet few modifiable behaviors counter this genetic vulnerability....
